Clinical Trials Logo

Clinical Trial Summary

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (ICHD 2018). Migraine can be further categorized according to the frequency of attacks as episodic migraine (EM) or chronic migraine (CM). This study will assess the effects of BOTOX in preventing migraine in adult participants with EM. BOTOX is being developed for the prevention of migraine in adults with episodic migraine (EM). Participants will be enrolled in 3 different treatment groups. There is 1 in 3 chance that participants will be assigned to receive placebo. Approximately 777 adult participants with EM will be enrolled in approximately 125 sites across the world. Participants will receive intramuscular injections (injected into the muscle) of BOTOX or Placebo on Week 0 and Week 12. Eligible participants will receive BOTOX on Week 24 and Week 36. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05028569
Study type Interventional
Source Allergan
Phone 844-663-3742
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date September 27, 2021
Completion date November 26, 2023

See also
  Status Clinical Trial Phase
Completed NCT02569853 - DFN-11 Injection in Episodic Migraine With or Without Aura Phase 3
Completed NCT00719134 - The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache Phase 4
Completed NCT03700320 - Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine Phase 3
Not yet recruiting NCT05042037 - Probiotics as Adjunctive Migraine Prophylaxis N/A
Recruiting NCT04628429 - CGRP Inhibition, Autonomic Function, and Migraine
Withdrawn NCT01257893 - Aspirin Resistance in Women With Migraine N/A
Completed NCT03132233 - Energy for the Brain N/A
Completed NCT03939312 - Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine Phase 3
Active, not recruiting NCT03927144 - Study of Sustained Benefit of Erenumab in Adult Episodic Migraine Patients Phase 4
Completed NCT04031781 - The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis N/A
Recruiting NCT04740827 - Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. Phase 3
Recruiting NCT04828941 - My Healthy Diary - An Electronic Diary for Remote Migraine Monitoring N/A
Completed NCT03096834 - A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies Phase 3
Recruiting NCT03432286 - A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine Phase 3
Recruiting NCT01230411 - A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack Phase 4
Enrolling by invitation NCT04437433 - A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine Phase 3
Completed NCT04166045 - Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain N/A
Active, not recruiting NCT03963232 - A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine Phase 3
Completed NCT00868556 - fMRI of the Brainstem in Migraine Sufferers and Controls. Does Iron Deposition Correlate With Progression of Disease? N/A
Completed NCT03333109 - Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients Phase 3